David C. Hastings served as the Chief Financial Officer (CFO) at Arbutus Biopharma Corp, a biopharmaceutical company focused on discovering, developing, and commercializing a cure for chronic hepatitis B virus infection. During his tenure, Hastings played a pivotal role in steering the financial strategy of the company, ensuring its fiscal health and supporting its growth trajectory. His leadership was instrumental in navigating the complex financial landscape of the biopharmaceutical industry, which often requires substantial investment in research and development. Before joining Arbutus Biopharma Corp, Hastings amassed a wealth of experience in the financial sector, particularly within the life sciences industry. His career included significant roles at various companies where he honed his expertise in financial management, strategic planning, and corporate governance. Hastings's strategic vision and deep understanding of the industry's financial dynamics enabled him to make critical decisions that supported Arbutus's mission to advance its therapeutic pipeline and bring innovative treatments to market. As CFO, one of Hastings's notable achievements was his ability to secure funding and manage resources effectively, ensuring that Arbutus could continue its research and development efforts without interruption. His contributions extended beyond mere financial oversight; he was a key member of the executive team, providing insights that shaped the company's overall strategy. Although he is no longer with Arbutus Biopharma Corp, Hastings's legacy continues to influence the company's financial stability and its pursuit of groundbreaking treatments for hepatitis B.